Jazz Pharmaceuticals plc — Director's Dealing 2024

Jan 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2024-01-17

Reporting Person: Pearce Samantha (SVP, Head of Europe & Internat)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-17	Ordinary Shares	A	2210	$0.0	Acquired	15369	Direct
2024-01-17	Ordinary Shares	F	1038	$119.13	Disposed	14331	Direct

Footnotes

F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified.

F2: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.